Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
HKSE: 0874.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hong Li
- Employees
- 28,138
- Headquarters
- Guangzhou, China
- IPO year
- 1997
- Market cap
- HK$41.6B
- Website
- https://www.gybys.com.cn
Loading 0874…
Loading profile data…Frequently asked questions about 0874
What does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) do?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationa...
Where does 0874.HK trade?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) trades on the Hong Kong Stock Exchange.
What sector is 0874.HK in?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited?
Hong Li is the chief executive officer of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK).
Where is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited headquartered?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is headquartered in China.
Does 0874.HK pay a dividend?
Yes — Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) paid a trailing twelve-month dividend of HKD 0.88 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 0874.HK go public?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) completed its initial public offering in 1997.